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Abstract: Sunitinib, a small molecule, is a multitargeted receptor
kinase inhibitor which targets the vascular endothelial growth factor
receptor and platelet-derived growth factor receptor as well as
several others. Initially approved for the treatment of renal cell
carcinoma as well as imatinib-resistant gastrointestinal stromal tu-
mors, the activity of sunitinib has been explored in several other
solid tumors including non-small cell lung cancer (NSCLC). An
initial phase II trial in 63 previously treated NSCLC patients using
a dose of 50 mg daily 4 of 6 weeks showed a response rate of 11.1%
and a stable disease rate of 26.8%. The median time to disease
progression and overall survival was 12.0 and 23.4 weeks, respec-
tively. The principal toxicities included fatigue, pain, myalgias,
nausea/vomiting, and hypertension. Three hemorrhagic deaths were
reported (two pulmonary and one central nervous system). After this
trial was completed, a subsequent sequential cohort of 47 previously
treated NSCLC patients were treated on a continuous dosing sched-
ule of sunitinib at 37.5 mg daily. A response rate of 2.1% was
reported with a stable disease rate of 19.X%. The median time to
progression was 12.3 weeks with a median survival time of 38.1
week. Toxicities were, in general, less frequent and similar to those
noted in the initial trial. Sunitinib is currently being evaluated in
combination with a number of standard regimens commonly used in
NSCLC as well as a maintenance drug after first-line platinum-based
treatment of advanced NSCLC. Results of these trials are eagerly
awaited and will help define the role of sunitinib in the therapeutic
approach to NSCLC.
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Sunitinib is a small molecule (Figure 1) that inhibits severalmembers of the receptor tyrosine kinase (RTK) family,
including vascular endothelial cell growth factor (VEGF) re-
ceptors types 1 and 2, platelet-derived growth factor (PDGF)
receptors  and , CSF-1R, c-KIT, FLT3, and RET.1 RTKs
are transmembrane proteins that transduce extracellular sig-
nals to the cytoplasm. Stimulation of these receptors results in
cell proliferation and angiogenesis and enhances the meta-
static potential of the malignant cell.2,3 Successful inhibition
of these RTKs has the potential to significantly alter the
course of any hematologic or solid tumor malignancy where
cell proliferation, angiogenesis, and metastasis are mediated
by these RTKs.4
VEGF is one of the principal proangiogenic factor used
by solid tumors to promote angiogenesis.3,4 PDGF is up-
regulated during tumor progression, thereby stimulating the
proliferation of pericytes and fibroblast needed to support the
growing neovasculature.4 PDGF has 2 receptors,  and ,
which are frequently overexpressed in many solid tumors and
their surrounding stoma,2,5 Basic fibroblast growth factor and
its receptor are expressed in many solid tumors and appear to
be involved in promoting their growth.6 Recent studies have
suggested that both VEGF and PDGF play an important role
in non-small cell lung cancer (NSCLC).6–8 Elevated expres-
sion of VEGF is a strong prognostic indicator in NSCLC and
is associated with early relapse and decreased survival in
early-stage NSCLC.6 Increased expression of PDGF has also
been shown to be associated with a poor prognosis in
NSCLC.7 In addition, these pathways may cooperate in neo-
angiogenesis as was suggested by Shikada et al.8 Given these
data, the VEGF and PDGF pathways may be key targets in
NSCLC, making therapies directed at these pathways a ra-
tional approach in this disease.1
Sunitinib is currently approved in the United States for
the treatment of advanced renal cell carcinoma and imatinib-
refractory gastrointestinal stromal tumors. As noted above,
sunitinib is an inhibitor of both the VEGF and PDGF path-
ways and has shown clinical activity in renal cell carcinoma,
gastrointestinal stromal tumors, breast cancer, and other solid
tumors. In phase 1 trials, the initial dosage identified for use
in most phase 2 trials was 50 mg/d orally for either 2 or 4
weeks followed by a 2-week rest period (2/2 and 4/2 sched-
ule, respectively).9 Sunitinib is metabolized by the CYP3A4
pathway to the active metabolite, SU012662.9,10 Clearance is
predominantly via the hepatic/biliary elimination.9,10 The
half-life of sunitinib is approximately 40 hours, whereas that
of SU012662 is approximately 80 hours.11 Because of these
long half-lives, rest periods were incorporated in the original
schedules, allowing recovery from the common toxic effects
of sunitinib, which included fatigue, diarrhea, nausea, mu-
cositis, hypertension, myelosuppression, and skin abnormal-
ities.9–11 The observation in preclinical models that tumor
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growth occurred during the rest periods suggested that con-
tinuous dosing may be more effective.9–11 Although both
intermittent and continuous dosing strategies are currently
being evaluated in ongoing clinical trials, the optimal sched-
ule has not been defined.
SUNITINIB IN NSCLC
The initial phase 2 trial evaluating the role of sunitinib
in NSCLC was performed in previously treated patients with
advanced NSCLC.12 The dosage used in the initial trial was
50 mg/d orally for 4 weeks followed by a 2-week rest (4/2
schedule). The eligibility criteria for this trial included only
performance status (PS) 0 to 1 patients who had received a
platinum-based regimen after which progression was docu-
mented. Up to two prior regimens were allowed. Patients
were excluded if they had recent gross hemoptysis or evi-
dence of brain metastases. All histologic types of NSCLC
were allowed. Sixty-three patients were entered into the trial.
The characteristics of the patients were as follows: a median
age of 60 years (range, 33–86 years), 65% were male, 44%
were PS 0 and 56% were PS 1, 64% had adenocarcinoma
whereas 22% had squamous carcinoma, 90% had stage IV
disease (10% had stage IIIB), and 16% were never-smokers.
The median treatment duration of sunitinib was 11 weeks
(range, 1–54 weeks). Twenty-four percent of patients re-
quired dose interruption (most commonly due to an adverse
event), whereas 22% required a dose reduction. The principal
toxic effects observed in this initial cohort included fatigue
(27% grade 3–4), pain or myalgia (17% grade 3–4), nausea
or vomiting (10% grade 3–4), and hypertension (5% grade 3).
Myelosuppression was minimal, with only a 5% rate of either
grade 3 to 4 neutropenia or thrombocytopenia. Three hemor-
rhagic deaths occurred: two pulmonary and one central ner-
vous system. The two pulmonary hemorrhagic deaths were
seen in patients with squamous carcinoma, one of which was
believed prospectively to be secondary to disease progres-
sion. The occurrences of hemorrhagic deaths is similar to the
experience with bevacizumab13,14 and suggest a relationship
between antiangiogenic treatment and hemorrhage which
may be heightened in patients with squamous histology.
A response rate of 11.1% (95% confidence interval
[CI], 4.6–21.6%) was observed, with a stable disease rate of
28.6%. The median time to progression was 12.0 weeks, with
a median survival time 23.4 weeks. The 1-year survival rate
was 20.2%. The activity observed was similar to the activity
of currently approved agents in this patient population, such
as docetaxel, pemetrexed, erlotinib, and gefitinib.15–17
After this initial experience, it was decided to explore a
continuous dosing schedule in the same population given the
uncertainty of the optimal schedule of sunitinib. A second
cohort of patients (using the identical eligibility and exclusion
criteria) was accrued to evaluate a continuous dosing sched-
ule of 37.5 mg/d orally.14 Since this was a sequential cohort,
caution must be exercised with regard to drawing any con-
clusions from a comparison of these two cohorts. Forty-seven
patients were accrued, and the characteristics of these addi-
tional patients were essentially identical to the initial cohort
of patients accrued to the 4/2 schedule. The median duration
of treatment with sunitinib was 92 days (range, 12–336 days).
Fifty-one percent required a dose interruption (most com-
monly due to an adverse event), whereas 29.8% required a
dose reduction to 25 mg/d orally. The principal toxic effects
included fatigue (17% grade 3–4), dyspnea (8.5% grade
3–4), hemoptysis (2.1% grade 3–4), and hypertension (6.4%
grade 3–4). There were no grade 4 hematologic toxic effects;
only 9% of patients experienced grade 3 neutropenia, with the
remaining hematologic toxic effects being grade 1 to 2. A
response rate of 2.1% (95% CI, 0.1–11.1) was observed, with
a 19.1% rate of disease stabilization. The median time to
progression was 12.3 weeks (95% CI, 8.9–16.0 weeks), and
the median survival time was 38.1 week (95% CI, 31.1 week
to not available). As noted above, these data cannot be
directly compared because the two trials were performed in a
sequential fashion. It can be concluded that both doses and
schedules showed activity in advanced refractory NSCLC.
With regard to toxic effects, both doses and schedules were
generally well tolerated, with the overall rate of grade 3 to 4
toxic effects somewhat less with the 37.5 mg continuous
dosing schedule. The efficacy results of these two cohorts are
summarized in Table 1.
ONGOING TRIALS AND CURRENT ISSUES
WITH SUNITINIB IN NSCLC
The data generated by the two trials noted above establish
sunitinib as an agent of interest in NSCLC and deserving of
further evaluation in this disease. Defining the optimal schedule
remains a priority with sunitinib, as is evaluating its role in
combination with standard agents or regimens currently used in
the treatment of advanced NSCLC. Table 2 summarizes the
ongoing sponsored trials evaluating sunitinib in combination
with standard agents and regimens in advanced NSCLC. Both
intermittent and continuous dosing schedules are being explored.
It remains to be seen how easily sunitinib will integrate into the
various strategies being explored in the phase 1 trials.
One concern is the toxicity profile of sunitinib as a
single agent and, in particular, the observation in the two
trials noted above14,17 that this agent has a low rate of
myelosuppression associated with it. This may exacerbate the
FIGURE 1. Molecular structure of sunitinib.
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neutropenia seen with platinum-based regimens similar to the
observation with bevacizumab in combination with carbopla-
tin and paclitaxel.14 This may be less of a concern when
adding it to single agents that have low rates of myelosup-
pression such as pemetrexed.15 Also, fatigue is a concern
because this is a common toxic effect associated with many
agents and regimens and a part of the disease process in lung
cancer that is often multifactorial. In addition, the use of
sunitinib in patients with brain metastases from NSCLC has
not been evaluated because these patients were excluded from
the trials discussed above. There is an ongoing trial in this
population designed to establish the safety of sunitinib in this
setting. Likewise, no histologic restrictions were placed on
the patients accrued to the single-arm trial noted above, but
the issue of safety as it relates to the risk of sunitinib in the
squamous cell population needs further definition. As noted,
two fatal pulmonary hemorrhages occurred in two patients
with squamous cell cancer in the phase 2 trial. Ongoing trials
are not excluding patients with squamous cell disease, but
this should be carefully evaluated as these trials complete
their accrual.
Another issue is how sunitinib should be integrated into
the overall treatment plan for patients with advanced NSCLC.
This is a complicated question because we currently have
three lines of approved agents and regimens, as well as
bevacizumab, for treatment choices for our patients. Is the
optimal use of sunitinib in combination with standard agents
and regimens or as a single agent integrated somewhere into
the already complicated treatment approach for these pa-
tients? There is not yet adequate data from the phase 1
experience to tell us how well sunitinib combines with other
agents and regimens and what dosage is possible with this
agent. The one exception is the combination of sunitinib with
erlotinib, which appears to be feasible at doses of 37.5 mg/d
orally in combination with 150 mg/d orally of erlotinib. This
was initially established in the run-in phase of a randomized
phase 2 trial, which is currently ongoing. The combination of
an anti-EGFR agent in combination with an anti-VEGF agent
is attractive, and the preliminary data in NSCLC with the
erlotinib/bevacizumab combination are encouraging and pro-
vide the rationale for other approaches targeting these path-
ways. An ongoing phase 3 trial is addressing whether
sunitinib in combination with erlotinib will improve survival
outcomes in patients with refractory NSCLC.
The Cancer and Leukemia Group B (CALGB) is ex-
ploring sunitinib in several unique ways. In CALGB 30607,
sunitinib is being evaluated as a maintenance agent compared
with placebo (Figure 2). In this trial, patients with advanced-
stage IIIB/IV NSCLC who have nonprogressing disease after
four cycles of platinum-based chemotherapy with or without
bevacizumab will be randomized to 37.5 mg/d orally of either
sunitinib or placebo. The primary objective of this trial is
prolongation of progression-free survival (PFS), with second-
ary objectives evaluating overall survival, additional re-
sponses as a result of sunitinib, safety and toxicity, and the
impact of sunitinib on the time to symptom progression in
this population. Although maintenance therapy in NSCLC
remains an unproven concept, recent data from a trial of
immediate versus delayed docetaxel in the same patient
population showed a significant improvement in PFS as a
TABLE 2. Ongoing Clinical Studies of NSCLC
Phase Description Sunitinib Dosage End Point
1 Docetaxel combination 2/1, 25–50 mg MTD, safety
1 Carboplatin/paclitaxel combination 2/1, 25–50 mg MTD, safety
1 Gemcitabine/cisplatin combination 2/1, 37.5–50 mg MTD, safety
2 First-line carboplatin/paclitaxel
consolidation therapy
4 cycles of chemotherapy;
4/2, 50 mg to PD
Survival at 1 yr
2 Erlotinib with or without Sunitinib CD, 37.5 mg PFS
3 Erlotinib with or without Sunitinib CD, 37.5 mg OS
1 Cisplatin/pemetrexed CD, 37.5–50 mg MTD, safety
1 Carboplatin/pemetrexed CD, 37.5–50 mg MTD, safety
1 Pemetrexed combination CD, 37.5–50 mg MTD, safety
CD indicates continuous dosing; MTD, maximum tolerated dose; OS, overall survival; PFS, progression-free
survival.
TABLE 1. Single-Agent Activity of Sunitinib in Advanced,
Refractory NSCLC
Socinski et al.12 Scagliotti et al.14
No. of patients 63 47
Dose (mg) 50 37.5
Schedule 4/2* Continuous
Efficacy
Partial response (%) (95% CI) 11.1 (4.6–21.6) 2.1 (0.1–11.3)
Stable disease (%)† 28.6 19.1
Median PFS, wk (95% CI) 12.0 (10.0–16.1) 12.3 (8.7–16.0)
MST, wk (95% CI) 23.4 (17.0–28.3) 38.1 (13.1–NA)
1-yr survival (%) 20.2 NA
Toxic effect (grade 3–4) (%)
Fatigue 29 17
Pain or myalgia 17 2
Nausea or vomiting 10 2
Dyspnea 11 11
Dehydration 8 0
* Four weeks on with a 2-wk rest period.
† For more than 8 wk.
CI indicates confidence interval; MST, mean survival time; NA, not available;
NSCLC, non–small cell lung cancer; PFS, progression-free survival.
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result of immediate or maintenance docetaxel.19 The use of a
well-tolerated, orally administered agent with once-a-day
dosing and demonstrated activity in advanced NSCLC seems
like a logical candidate to evaluate in such a design and
provides the rationale for CALGB 30607.
The observation of the activity of sunitinib, which is
similar to other currently approved agents in refractory
NSCLC, led to the design of CALGB 30704. This 3-arm
randomized phase 2 trial will test sunitinib against pem-
etrexed versus the combination of sunitinib plus pemetrexed
in the second-line setting. Again the primary end point is
PFS. This design is of interest because it addresses whether
sunitinib compares favorably with the approved cytotoxic
standard (pemetrexed) or adds to the efficacy of pemetrexed,
which may be the optimal manner in which to use antiangio-
genic agents. Lastly, sunitinib is being combined with cispla-
tin and etoposide in extensive-stage small cell lung cancer in
a phase 1/2 design. In the phase 2 portion of this trial, a
window-of-opportunity approach is being taken to explore
the single-agent activity of sunitinib in previously untreated
extensive-stage small cell lung cancer.
POTENTIAL SURROGATE BIOMARKERS
A surrogate end point is an outcome measure that
predicts clinical benefit in a selected population. With regard
to biomarkers, an outcome may be predicted based on a
laboratory or radiologic test and any given biomarker may be
helpful for prognostic as well as predictive information. As
angiogenesis is a critical and universal process and the role of
novel agents directed at the angiogenic process continues to
increase, the development of reliable biomarkers is currently
an area of intense investigation. Potential candidate biomar-
kers include soluable forms of pro-angiogenic growth factors
including VEGF-A, PIGF, stem cell factor and their receptors
as well as circulating endothelial cells and their progenitors
(CEPs). In addition, novel vascular imaging techniques such
as dynamic contrast-enhanced magnetic resonance imaging,
serial positron emission tomography scans and contrast-en-
hanced ultrasound may also provide important information
about the biologic effect of new agents. To date, there has not
been sufficient information published on the potential use of
these biomarkers in advanced NSCLC with sunitinib. Ongo-
ing studies are currently incorporating the use of putative
angiogenic biomarkers in a prospective fashion and hopefully
will enlighten this important area of research in NSCLC.20
SUMMARY
In conclusion, sunitinib is an active and tolerable agent
in advanced NSCLC. Ongoing trials are attempting to inte-
grate sunitinib with standard treatment agents and regimens
in advanced NSCLC and SCLC. A better understanding of
the mechanism of the fatigue associated with sunitinib should
be a priority. Likewise, understanding the mechanism of
resistance to sunitinib (both primary and acquired) and de-
termining if sunitinib has any activity in patients previously
treated with bevacizumab would help identify the optimal
patient for treatment with sunitinib.
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